Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cough algorithm for chronic cough in children: a multicenter, randomized controlled study.

Pediatrics·2013
Same author

Medication use in Indian children with asthma: the user's perspective.

Respirology (Carlton, Vic.)·2013
Same author

Medication use in Australian children with asthma: user's perspective.

The Journal of asthma : official journal of the Association for the Care of Asthma·2013
Same author

Medication use in children with asthma: not a child size problem.

The Journal of asthma : official journal of the Association for the Care of Asthma·2011
Same author

Diagnosis and management of asthma in adolescents.

The clinical respiratory journal·2010
Same author

Reduced exercise capacity in children born very preterm.

Pediatrics·2008

Related Experiment Video

Updated: May 28, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

That ICS should be first line therapy for asthma--con.

Peter Paul van Asperen1

  • 1Department of Respiratory Medicine, The Children's Hospitals at Westmead, Sydney Children's Hospital Network, (Randwick & Westmead), Westmead, Australia. peterv@chw.edu.au

Paediatric Respiratory Reviews
|October 25, 2011
PubMed
Summary

Leukotriene receptor antagonists (LTRAs) are recommended as the first-line asthma preventer therapy for most children. Inhaled corticosteroids (ICS) should be reserved for more severe cases, improving treatment adherence and reducing side effects.

Related Experiment Videos

Last Updated: May 28, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology
  • Allergy & Immunology

Background:

  • Asthma management in children is complex due to disease heterogeneity.
  • Current guidelines may not optimize first-line therapy for all pediatric asthma cases.

Purpose of the Study:

  • To evaluate leukotriene receptor antagonists (LTRAs) versus inhaled corticosteroids (ICS) as first-line asthma preventer therapy in children.
  • To determine optimal first-line treatment strategies based on asthma severity and specific triggers.

Main Methods:

  • Review of theoretical evidence and clinical trial data comparing LTRAs and ICS efficacy.
  • Analysis of adverse effect profiles and adherence factors for both medication classes.

Main Results:

  • LTRAs demonstrate superior efficacy in viral-induced wheezing and are equivalent to ICS in mild persistent asthma.
  • LTRAs offer a favorable safety profile with no systemic adverse effects and enhanced adherence due to once-daily oral administration.

Conclusions:

  • LTRAs should be considered first-line therapy for children with frequent intermittent or mild persistent asthma.
  • ICS should be reserved for moderate to severe persistent asthma cases.
  • This approach effectively addresses the needs of approximately two-thirds of children requiring asthma preventer medication.